A double-blind confirmatory study comparing rapid acting intramuscular olanzapine and intramuscular placebo in agitated patients with schizophrenia.

Trial Profile

A double-blind confirmatory study comparing rapid acting intramuscular olanzapine and intramuscular placebo in agitated patients with schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2009

At a glance

  • Drugs Olanzapine (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 28 Aug 2009 Actual patient number changed from 33 to 34 as reported by ClinicalTrials.gov.
    • 17 Aug 2008 Actual patient number added (33) as reported by ClinicalTrials.gov.
    • 17 Aug 2008 Actual end date added (July 2008) as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top